Tower Research Capital LLC recently announced the acquisition of new stake in Allarity Therapeutics Inc. (NASDAQ:ALLR). The institutional investor has increased its shareholding in the Healthcare company by 2,445.45% to 1400.0 shares with purchase of 1345.0 shares. This fresh investment now brings its stake to 0.01% valued currently at $616.0. In addition, Acadian Asset Management LLC raised its holdings by 1274.0 to 1274.0 shares.
With over 1.47 million Allarity Therapeutics Inc. (ALLR) shares trading Tuesday and a closing price of $0.28 on the day, the dollar volume was approximately $0.41 million. The shares have shown a negative half year performance of -98.06% and its price on 05/23/23 lost nearly -3.88%. Currently, there are 0.76M common shares owned by the public and among those 0.24M shares have been available to trade.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for ALLR have a consensus price objective of $8.00. The analysts have set the share’s price value over the next 12 months at a high of $8.00 and a low of $8.00. But an upside of 96.5% will see the stock hit the forecast high price target while median target price for the stock is $8.00.
The top 3 mutual fund holders in Allarity Therapeutics Inc. are Bridgeway Ultra Small Company Mar, Fidelity Series Total Market Inde, and Fidelity Extended Market Index Fu. Bridgeway Ultra Small Company Mar owns 571.0 shares of the company’s stock, all valued at over $251.0. Fidelity Extended Market Index Fu now owns shares totaling to 0.00% of the shares outstanding.
However, the script later moved the day high at 0.3020, down -3.88%. The company’s stock has a 5-day price change of -19.38% and -95.89% over the past three months. ALLR shares are trading -97.23% year to date (YTD), with the 12-month market performance down to -99.60% lower. It has a 12-month low price of $0.28 and touched a high of $118.30 over the same period. ALLR has an average intraday trading volume of 3.16 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -27.63%, -81.22%, and -98.29% respectively.
Institutional ownership of Allarity Therapeutics Inc. (NASDAQ: ALLR) shares accounts for 1.70% of the company’s 0.76M shares outstanding. Mutual fund holders own 0.01%, while other institutional holders and individual stakeholders account for 0.03% and — respectively.
It has a market capitalization of $5.78M. The earnings-per-share (ttm) stands at -$63.23. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.04% over the week and 13.67% over the month.
Analysts forecast that Allarity Therapeutics Inc. (ALLR) will achieve an EPS of -$7.88 for the current quarter, -$7.72 for the next quarter and -$19.82 for 2024. The lowest estimate earnings-per-share for the quarter is -$7.88 while analysts give the company a high EPS estimate of -$7.88. Earnings per share for the fiscal year are expected to increase by 47.30%, and 35.20% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Allarity Therapeutics Inc. (ALLR) as a “Hold” at a consensus score of 3.00. Specifically, 0 Wall Street analysts polled rate the stock as a buy, while 1 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
